文献速递MDS 与骨髓增殖性肿瘤

LSD1抑制剂bomedemstat治疗骨髓纤维化的1/2期研究结果

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.
PubMed 文献 · Blood Adv · 2026-01-01

常见不良事件为血小板减少(48%)和味觉障碍(36%),66%可评估患者脾体积缩小,56%可评估患者突变等位基因频率下降。

要点

  • bomedemstat在经治骨髓纤维化患者中安全性可控,常见不良事件为血小板减少和味觉障碍。
  • 可评估患者中66%脾体积缩小,26%缩小≥20%,疲劳等症状改善。
  • 56%可评估患者CALR/JAK2/MPL突变等位基因频率下降。

核心结论

  • bomedemstat在需要替代治疗的骨髓纤维化患者中具有可控的安全性和临床活性。

研究设计与样本

  • bomedemstat起始剂量为0.25、0.5或0.6 mg/kg每日一次口服,滴定至目标血小板计数≥50×10^9/L且≤75×10^9/L。
  • 主要终点为安全性和脾体积变化;血液学反应、症状负担、骨髓纤维化评分和VAF为探索性终点。

主要发现

  • 3例(3%)发生导致死亡的不良事件,均与治疗无关。
  • 35例有第24周脾体积数据的患者中,23例(66%)脾体积缩小,9例(26%)缩小≥20%。
  • 35例有基线和第24周数据的患者中,8例(23%)骨髓纤维化评分改善≥1级,21例(60%)稳定。
  • 36例有CALR、JAK2或MPL突变且第24周有数据的患者中,56%突变等位基因频率下降。

关键数值与推荐

  • 目标血小板计数范围为≥50×10^9/L至≤75×10^9/L。
  • 脾体积缩小≥20%的患者比例为26%(9/35)。
  • 骨髓纤维化改善≥1级的患者比例为23%(8/35),稳定比例为60%(21/35)。
  • 突变等位基因频率下降的患者比例为56%(36例中)。

临床怎么用

  • 对于JAK抑制剂失败或不耐受的骨髓纤维化患者,bomedemstat可能提供一种替代治疗选择。
  • 治疗中需监测血小板计数和味觉障碍等不良事件,并按目标血小板范围进行剂量滴定。

局限性

  • 脾体积、骨髓纤维化和VAF等探索性终点数据仅来自部分患者,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapies are needed for myelofibrosis (MF), particularly after Janus kinase (JAK) inhibitor failure. This open-label, phase 1/2 study evaluated bomedemstat, an irreversible inhibitor of lysine-specific demethylase 1, in participants with MF refractory or resistant to, inadequately controlled by, or intolerant of approved therapies. Eighty-nine participants initially received bomedemstat at doses 0.25, 0.5, or 0.6 mg/kg orally once per day, titrated to achieve a target platelet count of ≥50 × 109/L to ≤75 × 109/L. Primary end points were safety and change in spleen volume. Hematologic response and change in symptom burden, bone marrow fibrosis score, and variant allele frequency (VAF) were exploratory. Eighty-seven (97%) participants experienced ≥1 any-cause adverse event (AE), most commonly thrombocytopenia (48%) and dysgeusia (36%); 62 (69%) participants experienced ≥1 grade 3 to 5 AE. Three participants (3%) experienced AEs that led to death; none were related to treatment. Of 35 participants with spleen volume data at week 24, 23 (66%) had a reduction in spleen volume; 9 (26%) had a reduction of ≥20%. Mean platelet and white blood cell counts normalized over 24 weeks; hemoglobin levels remained stable. Participants reported improvement in most symptoms, including fatigue. Of 35 participants with baseline and week 24 data, 8 (23%) had improved bone marrow fibrosis by ≥1 grade per central review, and 21 (60%) were stable. Of 36 participants with CALR, JAK2, or MPL mutations and data at week 24, 56% had a reduction in VAF. Bomedemstat had manageable safety and clinical activity in participants with MF in need of an alternative therapy. This trial was registered at www.ClinicalTrials.gov as NCT03136185.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gill H, Yacoub A, Gerds AT, et al. The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study. Blood Adv. 2026. PMID: 42054549. doi:10.1182/bloodadvances.2025018141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。